Table 3.
Univariate and multivariate analysis of overall dose‐limiting toxicity
| Univariate analysis a | Multivariate analysis b | Multivariate analysis b | ||
|---|---|---|---|---|
| SMM | SMD | |||
| Characteristics | N = 297 | Crude OR (95% CI) | Adjusted OR c (95% CI) | Adjusted OR d (95% CI) |
| SMM status | ||||
| Intermediate | 99 | Ref. | Ref. | Ref. |
| Low | 99 | 1.94 (1.10–3.44) | 2.23 (1.23–4.04)* | 2.11 (1.12–3.98)* |
| High | 99 | 1.22 (0.70–2.14) | 1.16 (0.66–2.03) | 1.25 (0.69–2.25) |
| SMD status | ||||
| Intermediate | 95 | Ref. | Ref. | |
| Low | 95 | 1.10 (0.61–1.97) | 0.94 (0.50–1.75) | |
| High | 94 | 0.40 (0.22–0.71) | 0.41 (0.23–0.74)* | |
| Gender | ||||
| Male | 167 | Ref. | ||
| Female | 130 | 1.17 (0.74–1.85) | ||
| Age at diagnosis in years | ||||
| ≤65 years | 142 | Ref. | ||
| >65 years | 155 | 1.11 (0.70–1.75) | ||
| ECOG PS | ||||
| 0 | 115 | Ref. | ||
| 1 | 133 | 1.22 (0.74–2.01) | ||
| ≥2 | 8 | 1.48 (0.34–6.47) | ||
| 1.03 (0.50–2.10) | ||||
| BMI (kg/m2) | ||||
| 18.5 to <25 | 119 | Ref. | Ref. | Ref. |
| <18.5 | 11 | 0.74 (0.21–2.56) | 0.56 (0.16–2.01) | 0.56 (0.13–2.32) |
| 25 to <30 | 116 | 1.17 (0.70–1.96) | 1.36 (0.79–2.32) | 1.25 (0.71–2.19) |
| ≥30 | 51 | 1.38 (0.71–2.69) | 1.66 (0.83–3.33) | 1.44 (0.68–3.06) |
| Charlson co‐morbidity index # | ||||
| 2–3 | 100 | Ref. | ||
| 4–5 | 98 | 1.23 (0.70–2.16) | ||
| >6 | 99 | 1.25 (0.72–2.19) | ||
| Renal function (mL/min/1.73 m2) | ||||
| ≥60 | 273 | Ref. | ||
| <60 | 24 | 2.05 (0.82–5.12) | ||
| Serum albumin (g/L) | ||||
| ≥37.5 | 190 | Ref. | ||
| <37.5 | 81 | 1.48 (0.87–2.52) | ||
| BSA (m2) | 297 | 1.16 (0.41–3.30) | ||
| Weight (kg) | 297 | 1.00 (0.99–1.02) |
Univariate logistic regression analysis.
Multivariate logistic regression analysis (Backward: Wald).
Adjusted odds ratio: adjusted for SMM status and BMI in multivariate logistic regression analysis.
Adjusted odds ratio: adjusted for SMD status, SMM status, and BMI in multivariate logistic regression analysis.
P‐value < 0.05.
Charlson co‐morbidity index score provides a simple means to quantify the effect of co‐morbid illnesses, including cardiovascular diseases, chronic obstructive pulmonary disease, liver disease, and diabetes mellitus, among others and accounts for the aggregate effect if multiple concurrent diseases. A higher score indicates more co‐morbidities.
BMI, body mass index; BSA, body surface area; ECOG PS, Eastern Cooperative Oncology Group Performance Status; OR, odds ratio; SD, standard deviation; SMD, skeletal muscle density; SMM, skeletal muscle mass.